Current Environment: Production

Medical Services

Specialties

Programs & Services

Languages

  • English

Education

Undergraduate School

Harvard University

1985, Cambridge, MA

Medical School

University of Massachusetts Medical School

1990, Worcester, MA

Internship

Johns Hopkins Hospital

1991, Baltimore, MD

Residency

Johns Hopkins Hospital

1993, Baltimore, MD

Fellowship

Pediatric Gastroenterology

Boston Children's Hospital

1994, Boston, MA

Fellowship

Cell Biology

Boston Children's Hospital

1996, Boston, MA

Fellowship

Pfizer Fellowship in Clinical Investigation

Beth Israel Deaconess Medical Center

2002, Boston, MA

Certifications

  • American Board of Pediatrics (Gastroenterology)
  • Safe Zone Trained

Professional History

Assistant Professor of Pediatrics at HMS.  I also serve as Program Director for the HMS Fellowship in Pediatric Gastroenterology and Nutrition.

Media

Caregiver Profile

Meet Dr. Paul Rufo

Publications

  1. Clinical outcomes of maintenance therapy with sulfasalazine compared to 5-aminosalicylates in children with ulcerative colitis. J Pediatr Gastroenterol Nutr. 2025 Apr 10. View Abstract

  2. Higher alpha diversity and Lactobacillus blooms are associated with better engraftment after fecal microbiota transplant in inflammatory bowel disease. Sci Rep. 2024 08 06; 14(1):18188. View Abstract

  3. Evaluation and novel treatment in a case of refractory small bowel-small bowel intussusception. JPGN Rep. 2024 Aug; 5(3):367-370. View Abstract

  4. Inpatient management of iron deficiency anemia in pediatric patients with inflammatory bowel disease: A single center experience. World J Clin Pediatr. 2024 Mar 09; 13(1):89318. View Abstract

  5. Analysis of missed clinic visits, preferred languages, and telemedicine in a pediatric gastroenterology practice. J Pediatr Gastroenterol Nutr. 2024 May; 78(5):1069-1081. View Abstract

  6. Efficacy and Safety of Tacrolimus or Infliximab Therapy in Children and Young Adults With Acute Severe Colitis. J Pediatr Gastroenterol Nutr. 2023 08 01; 77(2):222-227. View Abstract

  7. Advancing Health Equity and Inclusion in an Academic Pediatric Medical Center: Priorities Addressed and Lessons Learned. J Pediatr Soc North Am. 2023 Feb 15; 5(Suppl 1):618. View Abstract

  8. Higher alpha diversity and Lactobacillus blooms are associated with better engraftment after Fecal Microbiota Transplant in Inflammatory Bowel Disease. medRxiv. 2023 Feb 01. View Abstract

  9. Efficacy and Safety of Sulfasalazine Suspension in Children With Ulcerative Colitis. J Pediatr Gastroenterol Nutr. 2023 04 01; 76(4):460-467. View Abstract

  10. The Specific Carbohydrate Diet: Obstacle and Opportunities. JPGN Rep. 2022 Aug; 3(3):e240. View Abstract

  11. Efficacy and Safety of High-dose Cholecalciferol in Patients With Inflammatory Bowel Disease Receiving Infliximab. J Pediatr Gastroenterol Nutr. 2022 04 01; 74(4):476-483. View Abstract

  12. Stratification of risk of progression to colectomy in ulcerative colitis via measured and predicted gene expression. Am J Hum Genet. 2021 09 02; 108(9):1765-1779. View Abstract

  13. Analysis of Using the Total White Blood Cell Count to Define Severe New-onset Ulcerative Colitis in Children. J Pediatr Gastroenterol Nutr. 2020 09; 71(3):354-360. View Abstract

  14. Protein-Losing Enteropathy in the Setting of Iron Deficiency Anemia: A Case Series. JPGN Rep. 2020 Nov; 1(2):e009. View Abstract

  15. Pediatric Collagenous Gastroenterocolitis Successfully Treated with Methotrexate. Case Rep Pediatr. 2020; 2020:1929581. View Abstract

  16. Screening and Counseling for Alcohol Use in Adolescents With Chronic Medical Conditions in the Ambulatory Setting. J Adolesc Health. 2019 06; 64(6):804-806. View Abstract

  17. Clinical and biological predictors of response to standardised paediatric colitis therapy (PROTECT): a multicentre inception cohort study. Lancet. 2019 04 27; 393(10182):1708-1720. View Abstract

  18. Ulcerative colitis mucosal transcriptomes reveal mitochondriopathy and personalized mechanisms underlying disease severity and treatment response. Nat Commun. 2019 01 03; 10(1):38. View Abstract

  19. Effectiveness of oral iron supplementation in treatment of anemia associated with pediatric ulcerative colitis flare. Am J Hematol. 2018 12; 93(12):E404-E406. View Abstract

  20. Compositional and Temporal Changes in the Gut Microbiome of Pediatric Ulcerative Colitis Patients Are Linked to Disease Course. Cell Host Microbe. 2018 10 10; 24(4):600-610.e4. View Abstract

  21. Serologic Reactivity Reflects Clinical Expression of Ulcerative Colitis in Children. Inflamm Bowel Dis. 2018 05 18; 24(6):1335-1343. View Abstract

  22. Commentary: Button Batteries in Fidget Spinners: Is It Time to Push the "Panic Button"? J Pediatr Gastroenterol Nutr. 2018 04; 66(4):557-558. View Abstract

  23. Enhanced Contribution of HLA in Pediatric Onset Ulcerative Colitis. Inflamm Bowel Dis. 2018 03 19; 24(4):829-838. View Abstract

  24. Protein-Losing Enteropathy in the Setting of Severe Iron Deficiency Anemia. J Investig Med High Impact Case Rep. 2018 Jan-Dec; 6:2324709618760078. View Abstract

  25. Histologic Correlates of Clinical and Endoscopic Severity in Children Newly Diagnosed With Ulcerative Colitis. Am J Surg Pathol. 2017 Nov; 41(11):1491-1498. View Abstract

  26. The Role of Environmental Factors in the Pathogenesis of Inflammatory Bowel Diseases: A Review. JAMA Pediatr. 2017 10 01; 171(10):999-1005. View Abstract

  27. A randomized controlled trial of levodopa in patients with Angelman syndrome. Am J Med Genet A. 2018 05; 176(5):1099-1107. View Abstract

  28. Factors associated with early outcomes following standardised therapy in children with ulcerative colitis (PROTECT): a multicentre inception cohort study. Lancet Gastroenterol Hepatol. 2017 12; 2(12):855-868. View Abstract

  29. Correlation of endoscopic disease severity with pediatric ulcerative colitis activity index score in children and young adults with ulcerative colitis. World J Gastroenterol. 2017 May 14; 23(18):3322-3329. View Abstract

  30. Assessment of Fecal ASCA Measurement as a Biomarker of Crohn Disease in Pediatric Patients. J Pediatr Gastroenterol Nutr. 2017 02; 64(2):248-253. View Abstract

  31. A Screening Tool for Assessing Alcohol Use Risk among Medically Vulnerable Youth. PLoS One. 2016; 11(5):e0156240. View Abstract

  32. Health Care Maintenance in Adolescents with Inflammatory Bowel Disease. Adolesc Med State Art Rev. 2016; 27(1):177-92. View Abstract

  33. Electrophysiological Studies into the Safety of the Anti-diarrheal Drug Clotrimazole during Oral Rehydration Therapy. PLoS Negl Trop Dis. 2015 Sep; 9(9):e0004098. View Abstract

  34. Inflammatory bowel disease and neoplasia in children. Dig Dis. 2014; 32(4):455-62. View Abstract

  35. NASPGHAN guidelines for training in pediatric gastroenterology. J Pediatr Gastroenterol Nutr. 2013 Jan; 56 Suppl 1:S1-8. View Abstract

  36. Health supervision in the management of children and adolescents with IBD: NASPGHAN recommendations. J Pediatr Gastroenterol Nutr. 2012 Jul; 55(1):93-108. View Abstract

  37. Desquamative enteropathy and pyloric atresia without skin disease caused by a novel intracellular beta4 integrin mutation. J Pediatr Gastroenterol Nutr. 2008 Nov; 47(5):585-91. View Abstract

  38. Increased incidence of urinary matrix metalloproteinases as predictors of disease in pediatric patients with inflammatory bowel disease. Inflamm Bowel Dis. 2008 Aug; 14(8):1091-6. View Abstract

  39. Adalimumab for the treatment of Crohn-like colitis and enteritis in glycogen storage disease type Ib. J Inherit Metab Dis. 2008 Dec; 31 Suppl 3:505-9. View Abstract

  40. Adalimumab for the treatment of Crohn-like colitis and enteritis in glycogen storage disease type Ib. Journal of Inherited Metababolic Disease. 2008; [Epub ahead of print] .

  41. Challenges and progress in pediatric inflammatory bowel disease. Curr Opin Gastroenterol. 2007 Jul; 23(4):406-12. View Abstract

  42. Fecal lactoferrin is a sensitive and specific marker of disease activity in children and young adults with inflammatory bowel disease. J Pediatr Gastroenterol Nutr. 2007 Apr; 44(4):414-22. View Abstract

  43. Pancreatitis as the initial manifestation of stage IV neuroblastoma. J Pediatr Gastroenterol Nutr. 2007 Jan; 44(1):146-8. View Abstract

  44. Why good pouches go bad. Inflamm Bowel Dis. 2007 Jan; 13(1):116-7. View Abstract

  45. Pancreatitis as the intitial manifestation of Stage IV Neuroblastoma - A Case Report. Journal of Pediatric Gastroenterology Hepatology and Nutrition. 2007; 44(1):146-148.

  46. Fecal ASCA Measurements in the Assessment of Pediatric Patients with Crohn’s Disease (CD) or Suspected Inflammatory Bowel Disease (IBD). American College of Gastroenterology (Las Vegas, NV). 2006.

  47. Current Therapy of Inflammatory Bowel Disease in Children . Pediatric Drugs. 2006; 8(5):279-302.

  48. Current therapy of inflammatory bowel disease in children. Paediatr Drugs. 2006; 8(5):279-302. View Abstract

  49. Severe colitis in children. J Pediatr Gastroenterol Nutr. 2005 Oct; 41(4):375-85. View Abstract

  50. IBD in children: the more you look, the more you see.... Inflamm Bowel Dis. 2004 May; 10(3):327-8. View Abstract

  51. Serial Fecal Lactoferrin Measurements are Useful in the Interval Assessment of Patients with Active and Inactive Inflammatory Bowel Disease. Digestive Disease Week - American Gastroenterological Association. 2004.

  52. Diarrhea – Pediatric. The Encyclopedia of Gastroenterology. 2004; 1:585-593.

  53. The Detection of Lactoferrin, ASCA and ANCA in Feces is useful for Assessing Pediatric IBD Patients. Digestive Disease Week - American Gastroenterological Association. 2004.

  54. Anti-inflammatory Activities Displayed by Triphenyl and Imidazole Containing Compounds. 2004.

  55. Diarrhea-associated HIV-1 APIs potentiate muscarinic activation of Cl- secretion by T84 cells via prolongation of cytosolic Ca2+ signaling. Am J Physiol Cell Physiol. 2004 May; 286(5):C998-C1008. View Abstract

  56. Fecal lactoferrin is a sensitive and specific marker in identifying intestinal inflammation. Am J Gastroenterol. 2003 Jun; 98(6):1309-14. View Abstract

  57. Enhancement of intracellular Ca Signaling and Chloride Transport by Nelfinavir and Other Aspartyl Protease inhibitors. 2003.

  58. Pouchitis: Evolution of a New Form of Inflammatory Bowel Disease. Diarrhea Digest. 2000.

  59. The antifungal antibiotic, clotrimazole, inhibits chloride secretion by human intestinal T84 cells via blockade of distinct basolateral K+ conductances. Demonstration of efficacy in intact rabbit colon and in an in vivo mouse model of cholera. J Clin Invest. 1997 Dec 15; 100(12):3111-20. View Abstract

  60. Proteolytic activation of cholera toxin and Escherichia coli labile toxin by entry into host epithelial cells. Signal transduction by a protease-resistant toxin variant. J Biol Chem. 1997 Jun 13; 272(24):15562-8. View Abstract

  61. Proteolytic Activation of cholera toxin by Eschericia coli labile toxin by entry into host epithelial cells: signal transduction by a proteolytic resistant toxin variant. J. Biol. Chem. 1997; 272:15562-15568.

  62. The antifungal antibiotic, clotrimazole, inhibits Cl- secretion by polarized monolayers of human colonic epithelial cells. J Clin Invest. 1996 Nov 01; 98(9):2066-75. View Abstract

  63. Transcytosis of cholera toxin subunits across model human intestinal epithelia. Proc Natl Acad Sci U S A. 1995 Oct 24; 92(22):10094-8. View Abstract

  64. Pulmonology. The Harriet Lane Handbook, K.B. Johnson e.d. 1994; 80-94.

  65. How families cope with diabetes in adolescence. An approach and case analyses. Pediatrician. 1988; 15(1-2):80-94. View Abstract
BESbswy
BESbswy